Skip to Main Content
DownloadHi-Res Photo

Yibing Qyang, PhD

Associate Professor of Medicine (Cardiology) and of Pathology; Section of Cardiovascular Medicine

Contact Information

Yibing Qyang, PhD

Office Location

Qyang Laboratory
Download CV

Research Summary

Cardiovascular diseases are the number one cause of death worldwide, taking about 18 million lives each year. Our stem cell and regenerative medicine laboratory focuses on establishing novel cellular, tissue engineered, and animal models of human cardiovascular disease for the purpose of elucidating causative mechanisms and identifying therapeutic interventions to treat these diseases. Through a close collaboration with several clinicians at Yale, we are able to procure cells from healthy subjects and from those with clinically manifesting cardiovascular diseases. These cells include dermal fibroblasts derived from skin punch biopsies and peripheral mononuclear blood cells, which are reprogrammed into induced pluripotent stem cells (iPSCs) by introducing stem cell factors. iPSCs are self-renewable indefinitely and can differentiate into functional cardiovascular cells. Our unique position, made possible by Yale’s clinical resources, gives us the ability to derive unlimited numbers of patient specific cardiovascular cells for use in our investigations into cardiovascular disease mechanisms and the discovery of potential therapeutic treatments by performing high-throughput drug screening. This research paradigm also places our group in a great position to generate autologous, allogeneic or hypoimmunogenic “universal” stem cell based cardiovascular tissues for organ repair.

Specialized Terms: Cardiovascular; Heart; Stem cell; Regenerative Medicine; Tissue Engineering; Animal Models; ESC; iPSC; Physiology; Pathology; Patient; Small Molecule; Disease

Extensive Research Description

Our stem cell and regenerative medicine laboratory focuses on establishing novel cellular, tissue engineered, and animal models of human cardiovascular diseases for the purpose of elucidating causative mechanisms and identifying therapeutic interventions to treat these diseases. Our research covers the following areas:

1. Vascular tissue engineering and repair: Our group has used Sendai virus, integration-free technology to produce induced pluripotent stem cells (iPSCs) from somatic human donor cells via introduction of stem cell factors. iPSCs are self-renewable and can differentiate into functional vascular smooth muscle cells (VSMCs) and endothelial cells (ECs), providing an unlimited source of vascular cells for generation of tissue-engineered vascular grafts (TEVGs) for treating narrowing/blockage of arteries-the largest cause of mortality in the developed world.

We have generated mechanically robust small-diameter (2-4 mm) TEVGs by seeding human iPSC-VSMCs onto biodegradable polyglycolic acid (PGA) scaffolds in custom made bioreactors. Coupled with decellularization and subsequent re-endothelialization strategies using human iPSC-derived ECs (hiPSC-ECs) in both rat and pig models, our studies lay the foundation for the future production of therapeutic, “off the shelf” ready TEVGs for clinical use. Additionally, we are developing culture strategies to create fully cellular “universal” endothelialized hiPSC-TEVGs that are immunocompatible and readily available to any patient recipient. Recent studies were reported in Gui et al., Biomaterials 2016, 102:120-129 and Luo et al., Cell Stem Cell 2020, 26:251-261 in collaboration with Dr. Laura Niklason. New scientists are welcome to join and learn stem cell biology, tissue engineering, and animal modeling.

We have developed “universal” human iPSCs by using CRISPR-Cas9 technology to knock-out the adaptive immune mediating MHC class I and II molecules, paired with the ectopic expression of the macrophage and natural killer (NK) cell suppressor molecule CD47 with TALEN-mediated insertion at the AAVSI "safe harbor" gene locus. We utilize RRGS rats, which are deficient in T, B, and NK cells and allow effective immune humanization with human peripheral blood mononuclear cells (PBMCs), to assess the immunogenicity of engineered tissues using this “universal donor” cell line. Immune-humanized rats enable the investigation of the efficacy of decellularized hiPSC-TEVGs endothelialized with universal hiPSC-ECs, establishing the foundation for future assessments of this TEVG system in non-human primates as a therapeutic. New scientists can join this project and learn CRISPR and TALEN gene editing, tissue engineering, and immunology.

2. Vascular disease mechanisms and drug screening: Patient-specific vascular smooth muscle cells (VSMCs) facilitate the study of clinically manifesting vascular disease and the development of novel therapeutic interventions. We were the first to describe the development of a human induced pluripotent stem cell (iPSC) line from a patient with the vascular condition supravalvular aortic stenosis (SVAS). SVAS iPSC-VSMCs recapitulate key pathological features of patients with SVAS and provide a promising strategy to study disease mechanisms and to develop novel therapies (Ge et al., Circulation 2012, 126: 1695-1704; Dash et al., Stem Cell Reports 2016, 7: 19-28). The objectives of our research program are to obtain mechanistic insights into how elastin inhibits the hyperproliferation of SVAS iPSC-VSMCs in addition to screening for clinically applicable small molecules that ameliorate the hyperproliferative defect in SVAS. By studying SVAS, a disease with an intrinsic defect in VSMC proliferation, we may ultimately be able develop novel therapies for multiple vascular proliferative diseases. New scientists are welcome to join this project and learn vascular disease mechanisms and drug screening using patient stem cell modeling.

3. Mechanistic cardiac disease modeling: Human iPSCs provide a unique resource for generating patient-specific cardiomyocytes to study cardiac disease mechanisms for new treatments. We were the first group to report small molecule Wnt inhibitor IWP1 or IWP4-based, highly efficient production of functional cardiomyocytes from embryonic stem cells (ESCs) or iPSCs (Ren et al., J Mol Cell Cardiol 2011, 51: 280-7). We have used iPSC and tissue engineering approaches to study the functional consequences of sarcomeric and stretch-sensing mutations in hypertrophic cardiomyopathy (HCM; thickening of the heart tissue, affecting 1 out of 500 people). We have derived iPSCs from patients with MYH7 (sarcomeric) and MLP (stretch-sensing) mutations and are investigating mechanotransduction mediated disease mechanisms by producing engineered heart tissues (EHTs) that can be precisely stretched in collaboration with Dr. Stuart Campbell (manuscript under review). New scientists can join this project, gain experience in studying cardiac disease mechanisms, and learn how to design potential drug screening approaches to treat this devastating heart disease.

4. Congenital heart repair using human iPSC-derived ventricular cardiomyocytes: Single ventricle congenital heart defects (SVCHD) affect approximately 1 in 1000 live births and pose a prominent medical issue. Children born with these defects have a 70% mortality rate if there is no appropriate surgical intervention. The Fontan procedure consists of three surgeries spanning the first 2-3 years of life, which provides ample time to produce a personalized iPSC-based therapeutic. We have validated and optimized a modular design strategy for producing a contractile Fontan conduit that incorporates engineered heart tissues (EHTs) made by seeding iPSC-derived ventricular cardiomyocytes (iPSC-VCMs) into decellularized porcine heart matrices with a native fiber alignment that is crucial for force generation. Novel contractile Fontan conduits, currently named tissue engineered pulsatile conduits (TEPCs), have been developed by wrapping EHTs around decellularized human umbilical arteries (HUAs) to produce functional tissues capable of supporting blood flow and creating driving pressures (Park et al., Acta Biomater. 2020, 102:220-230). Importantly, TEPCs will further be subjected to biomimetic mechanical and electrical stimulation to induce maximal force production in bioreactors. New scientists can join this project and learn iPSC culture, cardiac differentiation, tissue engineering, and animal modeling.

5. Ischemic heart repair based on cardiac progenitor cells: We have established robust cardiac differentiation approaches in human embryonic stem cells (ESCs) and iPSCs to derive ISL1+ cardiovascular progenitor cells (ISL1-CPCs), a CPC population representative of an authentic cardiac origin, for repairing ischemic cardiac injury. We show that ISL1-CPCs have important physiological effects to improve heart contractile function, reduce scar size, and increase blood vessel formation in mouse models (Bartulos et al in Qyang group, JCI Insight 2016, 1:e80920). Thus, our findings indicate that the ISL1-CPC approach may represent a significant advance in the heart repair field. Future efforts will be made to translate ISL1-CPC heart repair from the mouse to large animal models. New scientists joining this project will learn how to isolate ISL1-CPCs from human ESCs and iPSCs, generate cardiac progenitor-based tissues, and gain experience in cardiac repair and regeneration.

6. Preclinical modeling of cardiovascular repair and regeneration: We have generated robust iPSC lines from pigs for the purpose of preclinical studies (Luo et al., Biomaterials 2017, 147:116-132). The availability of pig iPSCs will enable us to engineer the same kind of cardiovascular tissues we want to see used in the clinic, and then test them in pigs, which closely mimic human cardiovascular physiology. Our pig-to-pig studies will provide critical preclinical knowledge for the eventual application of human-to-human autologous and allogeneic stem cell-based cardiovascular repair and regeneration therapies. New scientists joining this project will learn how to derive functional cardiovascular cells from pig iPSCs for cardiovascular tissue engineering and investigate the therapeutic efficacy of engineered cardiovascular tissues in preclinical porcine models.

Coauthors

Research Interests

Animal Diseases; Cardiovascular Diseases; Heart; Pathology; Physiology; Stem Cells; Drugs, Investigational; Tissue Engineering; Regenerative Medicine; Embryonic Stem Cells; Induced Pluripotent Stem Cells

Public Health Interests

Aging; Bioinformatics; Biomarkers; Cardiovascular Diseases; Chronic Diseases; Clinical Trials; Genetics, Genomics, Epigenetics; Immunology; Obesity; Viruses; Women's Health; Toxicology

Research Images

Cardiovascular Disease Modeling and Drug Screening Using Patient iPSCs

Selected Publications

  • Xenogeneic-free generation of vascular smooth muscle cells from human induced pluripotent stem cells for vascular tissue engineering.Luo J, Lin Y, Shi X, Li G, Kural MH, Anderson CW, Ellis MW, Riaz M, Tellides G, Niklason LE, Qyang Y. Xenogeneic-free generation of vascular smooth muscle cells from human induced pluripotent stem cells for vascular tissue engineering. Acta Biomaterialia 2021, 119: 155-168 PubMed ID: 33130306, PMCID: PMC8168373, DOI: 10.1016/j.actbio.2020.10.042.
  • Efficient Differentiation of Human Induced Pluripotent Stem Cells into Endothelial Cells under Xenogeneic-free Conditions for Vascular Tissue Engineering.Luo J, Shi X, Lin Y, Yuan Y, Kural MH, Wang J, Ellis MW, Anderson CW, Zhang SM, Riaz M, Niklason LE, Qyang Y. Efficient Differentiation of Human Induced Pluripotent Stem Cells into Endothelial Cells under Xenogeneic-free Conditions for Vascular Tissue Engineering. Acta Biomaterialia 2021, 119: 184-196 PubMed ID: 33166710, PMCID: PMC8133308, DOI: 10.1016/j.actbio.2020.11.007.
  • Shortening Velocity Causes Myosin Isoform Shift in Human Engineered Heart Tissues.Ng R, Sewanan LR, Stankey P, Li X, Qyang Y, Campbell S. Shortening Velocity Causes Myosin Isoform Shift in Human Engineered Heart Tissues. Circulation Research 2021, 128: 281-283 PubMed ID: 33183160, PMCID: PMC7855774, DOI: 10.1161/CIRCRESAHA.120.316950.
  • Human-Induced Pluripotent Stem-Cell-Derived Smooth Muscle Cells Increase Angiogenesis to Treat Hindlimb Ischemia.Gao X, Gao M, Gorecka J, Langford J, Liu J, Luo J, Taniguchi R, Matsubara Y, Liu H, Guo L, Gu Y, Qyang Y, Dardik A. Human-Induced Pluripotent Stem-Cell-Derived Smooth Muscle Cells Increase Angiogenesis to Treat Hindlimb Ischemia. Cells 2021, 10 PubMed ID: 33918299, PMCID: PMC8066461, DOI: 10.3390/cells10040792.
  • An ex vivo physiologic and hyperplastic vessel culture model to study intra-arterial stent therapies.Wang J, Kural MH, Wu J, Leiby KL, Mishra V, Lysyy T, Li G, Luo J, Greaney A, Tellides G, Qyang Y, Huang N, Niklason LE. An ex vivo physiologic and hyperplastic vessel culture model to study intra-arterial stent therapies. Biomaterials 2021, 275: 120911 PubMed ID: 34087584, DOI: 10.1016/j.biomaterials.2021.120911.
  • PECUU-ECM Patches: The Future of Ischemic Heart Disease Repair.Ajaj Y, Akingbesote ND, Qyang Y. PECUU-ECM Patches: The Future of Ischemic Heart Disease Repair. JACC. Basic To Translational Science 2021, 6: 464-466 PubMed ID: 34101774, PMCID: PMC8165109, DOI: 10.1016/j.jacbts.2021.03.003.
  • Modular design of a tissue engineered pulsatile conduit using human induced pluripotent stem cell-derived cardiomyocytes.Park J, Anderson CW, Sewanan LR, Kural MH, Huang Y, Luo J, Gui L, Riaz M, Lopez CA, Ng R, Das SK, Wang J, Niklason L, Campbell SG, Qyang Y. Modular design of a tissue engineered pulsatile conduit using human induced pluripotent stem cell-derived cardiomyocytes. Acta Biomaterialia 2020, 102: 220-230 PubMed ID: 31634626, PMCID: PMC7227659, DOI: 10.1016/j.actbio.2019.10.019.
  • Tissue-Engineered Vascular Grafts with Advanced Mechanical Strength from Human iPSCs.Luo J, Qin L, Zhao L, Gui L, Ellis MW, Huang Y, Kural MH, Clark JA, Ono S, Wang J, Yuan Y, Zhang SM, Cong X, Li G, Riaz M, Lopez C, Hotta A, Campbell S, Tellides G, Dardik A, Niklason LE, Qyang Y. Tissue-Engineered Vascular Grafts with Advanced Mechanical Strength from Human iPSCs. Cell Stem Cell 2020, 26: 251-261.e8 PubMed ID: 31956039, PMCID: PMC7021512, DOI: 10.1016/j.stem.2019.12.012.
  • Induced pluripotent stem cell-derived smooth muscle cells increase angiogenesis and accelerate diabetic wound healing.Gorecka J, Gao X, Fereydooni A, Dash BC, Luo J, Lee SR, Taniguchi R, Hsia HC, Qyang Y, Dardik A. Induced pluripotent stem cell-derived smooth muscle cells increase angiogenesis and accelerate diabetic wound healing. Regenerative Medicine 2020, 15: 1277-1293 PubMed ID: 32228292, PMCID: PMC7304438, DOI: 10.2217/rme-2019-0086.
  • Modeling elastin-associated vasculopathy with patient induced pluripotent stem cells and tissue engineering.Ellis MW, Luo J, Qyang Y. Modeling elastin-associated vasculopathy with patient induced pluripotent stem cells and tissue engineering. Cellular And Molecular Life Sciences : CMLS 2019, 76: 893-901 PubMed ID: 30460472, PMCID: PMC6433159, DOI: 10.1007/s00018-018-2969-7.
  • Sarcomere-Directed Calcium Reporters in Cardiomyocytes.Campbell SG, Qyang Y, Hinson JT. Sarcomere-Directed Calcium Reporters in Cardiomyocytes. Circulation Research 2019, 124: 1151-1153 PubMed ID: 30973804, PMCID: PMC6527368, DOI: 10.1161/CIRCRESAHA.119.314877.
  • Patient mutations linked to arrhythmogenic cardiomyopathy enhance calpain-mediated desmoplakin degradation.Ng R, Manring HR, Papoutsidakis N, Albertelli T, Tsai N, See C, Li X, Park J, Stevens TL, Bobbili PJ, Riaz M, Ren Y, Stoddard CE, Janssen PM, Bunch TJ, Hall SP, Lo YC, Jacoby DL, Qyang Y, Wright N, Ackermann MA, Campbell SG. Patient mutations linked to arrhythmogenic cardiomyopathy enhance calpain-mediated desmoplakin degradation. JCI Insight 2019, 5 PubMed ID: 31194698, PMCID: PMC6675562, DOI: 10.1172/jci.insight.128643.
  • Extracellular Matrix From Hypertrophic Myocardium Provokes Impaired Twitch Dynamics in Healthy Cardiomyocytes.Sewanan LR, Schwan J, Kluger J, Park J, Jacoby DL, Qyang Y, Campbell SG. Extracellular Matrix From Hypertrophic Myocardium Provokes Impaired Twitch Dynamics in Healthy Cardiomyocytes. JACC. Basic To Translational Science 2019, 4: 495-505 PubMed ID: 31468004, PMCID: PMC6712054, DOI: 10.1016/j.jacbts.2019.03.004.
  • Vascular smooth muscle cells derived from inbred swine induced pluripotent stem cells for vascular tissue engineering.Luo J, Qin L, Kural MH, Schwan J, Li X, Bartulos O, Cong XQ, Ren Y, Gui L, Li G, Ellis MW, Li P, Kotton DN, Dardik A, Pober JS, Tellides G, Rolle M, Campbell S, Hawley RJ, Sachs DH, Niklason LE, Qyang Y. Vascular smooth muscle cells derived from inbred swine induced pluripotent stem cells for vascular tissue engineering. Biomaterials 2017, 147: 116-132 PubMed ID: 28942128, PMCID: PMC5638652, DOI: 10.1016/j.biomaterials.2017.09.019.
  • Stem Cells in Cardiovascular Medicine: the Road to Regenerative Therapies.Anderson CW, Boardman N, Luo J, Park J, Qyang Y. Stem Cells in Cardiovascular Medicine: the Road to Regenerative Therapies. Current Cardiology Reports 2017, 19: 34 PubMed ID: 28324469, PMCID: PMC5518932, DOI: 10.1007/s11886-017-0841-2.
  • ISL1 cardiovascular progenitor cells for cardiac repair after myocardial infarction.Bartulos O, Zhuang ZW, Huang Y, Mikush N, Suh C, Bregasi A, Wang L, Chang W, Krause DS, Young LH, Pober JS, Qyang Y. ISL1 cardiovascular progenitor cells for cardiac repair after myocardial infarction. JCI Insight 2016, 1 PubMed ID: 27525311, PMCID: PMC4982472, DOI: 10.1172/jci.insight.80920.
  • Anisotropic engineered heart tissue made from laser-cut decellularized myocardium.Schwan J, Kwaczala AT, Ryan TJ, Bartulos O, Ren Y, Sewanan LR, Morris AH, Jacoby DL, Qyang Y, Campbell SG. Anisotropic engineered heart tissue made from laser-cut decellularized myocardium. Scientific Reports 2016, 6: 32068 PubMed ID: 27572147, PMCID: PMC5004193, DOI: 10.1038/srep32068.
  • Tissue-Engineered Vascular Rings from Human iPSC-Derived Smooth Muscle Cells.Dash BC, Levi K, Schwan J, Luo J, Bartulos O, Wu H, Qiu C, Yi T, Ren Y, Campbell S, Rolle MW, Qyang Y. Tissue-Engineered Vascular Rings from Human iPSC-Derived Smooth Muscle Cells. Stem Cell Reports 2016, 7: 19-28 PubMed ID: 27411102, PMCID: PMC4945325, DOI: 10.1016/j.stemcr.2016.05.004.
  • Implantable tissue-engineered blood vessels from human induced pluripotent stem cells.Gui L, Dash BC, Luo J, Qin L, Zhao L, Yamamoto K, Hashimoto T, Wu H, Dardik A, Tellides G, Niklason LE, Qyang Y. Implantable tissue-engineered blood vessels from human induced pluripotent stem cells. Biomaterials 2016, 102: 120-9 PubMed ID: 27336184, PMCID: PMC4939127, DOI: 10.1016/j.biomaterials.2016.06.010.
  • Induced pluripotent stem cell-derived vascular smooth muscle cells: methods and application.Dash BC, Jiang Z, Suh C, Qyang Y. Induced pluripotent stem cell-derived vascular smooth muscle cells: methods and application. The Biochemical Journal 2015, 465: 185-94 PubMed ID: 25559088, PMCID: PMC4436659, DOI: 10.1042/BJ20141078.
  • Functional cardiomyocytes derived from Isl1 cardiac progenitors via Bmp4 stimulation.Cagavi E, Bartulos O, Suh CY, Sun B, Yue Z, Jiang Z, Yue L, Qyang Y. Functional cardiomyocytes derived from Isl1 cardiac progenitors via Bmp4 stimulation. PloS One 2014, 9: e110752 PubMed ID: 25522363, PMCID: PMC4270687, DOI: 10.1371/journal.pone.0110752.
  • Advancements in Induced Pluripotent Stem Cell Technology for Cardiac Regenerative Medicine.Suh CY, Wang Z, Bártulos O, Qyang Y. Advancements in Induced Pluripotent Stem Cell Technology for Cardiac Regenerative Medicine. Journal Of Cardiovascular Pharmacology And Therapeutics 2014, 19: 330-339 PubMed ID: 24651517, PMCID: PMC4169350, DOI: 10.1177/1074248414523676.
  • Modeling supravalvular aortic stenosis syndrome with human induced pluripotent stem cells.Ge X, Ren Y, Bartulos O, Lee MY, Yue Z, Kim KY, Li W, Amos PJ, Bozkulak EC, Iyer A, Zheng W, Zhao H, Martin KA, Kotton DN, Tellides G, Park IH, Yue L, Qyang Y. Modeling supravalvular aortic stenosis syndrome with human induced pluripotent stem cells. Circulation 2012, 126: 1695-704 PubMed ID: 22914687, PMCID: PMC3586776, DOI: 10.1161/CIRCULATIONAHA.112.116996.
  • Methods of cell purification: a critical juncture for laboratory research and translational science.Amos PJ, Cagavi Bozkulak E, Qyang Y. Methods of cell purification: a critical juncture for laboratory research and translational science. Cells, Tissues, Organs 2012, 195: 26-40 PubMed ID: 21996576, PMCID: PMC3257814, DOI: 10.1159/000331390.
  • Derivation of functional ventricular cardiomyocytes using endogenous promoter sequence from murine embryonic stem cells.Lee MY, Sun B, Schliffke S, Yue Z, Ye M, Paavola J, Bozkulak EC, Amos PJ, Ren Y, Ju R, Jung YW, Ge X, Yue L, Ehrlich BE, Qyang Y. Derivation of functional ventricular cardiomyocytes using endogenous promoter sequence from murine embryonic stem cells. Stem Cell Research 2012, 8: 49-57 PubMed ID: 22099020, PMCID: PMC3222859, DOI: 10.1016/j.scr.2011.08.004.
  • High density cultures of embryoid bodies enhanced cardiac differentiation of murine embryonic stem cells.Lee MY, Cagavi Bozkulak E, Schliffke S, Amos PJ, Ren Y, Ge X, Ehrlich BE, Qyang Y. High density cultures of embryoid bodies enhanced cardiac differentiation of murine embryonic stem cells. Biochemical And Biophysical Research Communications 2011, 416: 51-7 PubMed ID: 22079290, PMCID: PMC3237870, DOI: 10.1016/j.bbrc.2011.10.140.
  • Small molecule Wnt inhibitors enhance the efficiency of BMP-4-directed cardiac differentiation of human pluripotent stem cells.Ren Y, Lee MY, Schliffke S, Paavola J, Amos PJ, Ge X, Ye M, Zhu S, Senyei G, Lum L, Ehrlich BE, Qyang Y. Small molecule Wnt inhibitors enhance the efficiency of BMP-4-directed cardiac differentiation of human pluripotent stem cells. Journal Of Molecular And Cellular Cardiology 2011, 51: 280-7 PubMed ID: 21569778, PMCID: PMC3334336, DOI: 10.1016/j.yjmcc.2011.04.012.
  • The renewal and differentiation of Isl1+ cardiovascular progenitors are controlled by a Wnt/beta-catenin pathway.Qyang Y, Martin-Puig S, Chiravuri M, Chen S, Xu H, Bu L, Jiang X, Lin L, Granger A, Moretti A, Caron L, Wu X, Clarke J, Taketo MM, Laugwitz KL, Moon RT, Gruber P, Evans SM, Ding S, Chien KR. The renewal and differentiation of Isl1+ cardiovascular progenitors are controlled by a Wnt/beta-catenin pathway. Cell Stem Cell 2007, 1: 165-79 PubMed ID: 18371348, DOI: 10.1016/j.stem.2007.05.018.
  • Myeloproliferative disease in mice with reduced presenilin gene dosage: effect of gamma-secretase blockage.Qyang Y, Chambers SM, Wang P, Xia X, Chen X, Goodell MA, Zheng H. Myeloproliferative disease in mice with reduced presenilin gene dosage: effect of gamma-secretase blockage. Biochemistry 2004, 43: 5352-9 PubMed ID: 15122901, DOI: 10.1021/bi049826u.
  • The p21-activated kinase, Shk1, is required for proper regulation of microtubule dynamics in the fission yeast, Schizosaccharomyces pombe.Qyang Y, Yang P, Du H, Lai H, Kim H, Marcus S. The p21-activated kinase, Shk1, is required for proper regulation of microtubule dynamics in the fission yeast, Schizosaccharomyces pombe. Molecular Microbiology 2002, 44: 325-34 PubMed ID: 11972773, DOI: 10.1046/j.1365-2958.2002.02882.x.
  • Cell-type-dependent activity of the ubiquitous transcription factor USF in cellular proliferation and transcriptional activation.Qyang Y, Luo X, Lu T, Ismail PM, Krylov D, Vinson C, Sawadogo M. Cell-type-dependent activity of the ubiquitous transcription factor USF in cellular proliferation and transcriptional activation. Molecular And Cellular Biology 1999, 19: 1508-17 PubMed ID: 9891084, PMCID: PMC116079.
  • Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutation.Sewanan LR, Park J, Rynkiewicz MJ, Racca AW, Papoutsidakis N, Schwan J, Jacoby DL, Moore JR, Lehman W, Qyang Y, Campbell SG. Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutation. The Journal Of General Physiology 2021, 153 PubMed ID: 34319370, PMCID: PMC8321830, DOI: 10.1085/jgp.202012640.
  • Methods for Differentiating hiPSCs into Vascular Smooth Muscle Cells.Li ML, Luo J, Ellis MW, Riaz M, Ajaj Y, Qyang Y. Methods for Differentiating hiPSCs into Vascular Smooth Muscle Cells. Methods In Molecular Biology (Clifton, N.J.) 2022, 2375: 21-34 PubMed ID: 34591296, DOI: 10.1007/978-1-0716-1708-3_3.
Edit Profile